CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,619
- in 1 filing, $6K under 10b5-1 plans
Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | Seth Alpna Director | Sale 10b5-1 | −2,625 | $10.72 | $28K | 9,767 |
| 2026-06-03 | Seth Alpna Director | Grant or award | +7,142 | 12,392 | ||
| 2026-06-03 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +7,433 | 7,433 | ||
| 2025-06-04 | Seth Alpna Director | Grant or award | +5,250 | 5,250 | ||
| 2025-06-04 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +10,500 | 10,500 | ||
| 2024-05-30 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2023-06-06 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2023-05-01 | Seth Alpna Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 |
Page 1 of 1 · 8 trades